Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Novavax COVID-19 Vaccine
NVX-CoV2372 · 1 trial · 2 indications
Antibody concentrations 1 month after the recombinant vaccine booster (V2) in patients with IBD and solid organ transplant recipients compared to their baseline visit (V1).
| Arm | Type | Description |
|---|---|---|
| Participants who have had Solid Organ Transplants | EXPERIMENTAL | Male and females aged 18 to 85 who are solid organ transplant recipients and receive the study intervention. |
| Participants with IBD | EXPERIMENTAL | Male and females aged 18 to 85 who have IBD and receive the study intervention. |
| Name | Type | Description |
|---|---|---|
| NVX-CoV2372 | BIOLOGICAL | Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5 |
Inclusion Criteria: • Patient has a history of ulcerative colitis (UC), Crohn's disease, pouchitis, or indeterminate colitis diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria. And / or patient is a solid organ transplant recipient (e.g. lung, kidney, liver) * ...
NVX-CoV2372 is an investigational monoclonal antibody developed by Novavax, Inc. (ticker NVAX) for use in immunosuppressed populations. It is being studied for immunogenicity against COVID-19 in people with immunosuppression. The asset is in Phase 2 clinical development and has been evaluated in one completed trial.
NVX-CoV2372 is being developed to provide additional recombinant COVID-19 humoral and cell-mediated immunogenicity in immunosuppressed populations. The Phase 2 trial enrolled adults 18 years and older with immunosuppression and COVID-19. It is an investigational product and is not approved for any indication.
NVX-CoV2372 is developed by Novavax, Inc., which trades on the Nasdaq under the ticker NVAX. Novavax is the sponsor of the clinical program evaluating the monoclonal antibody in immunosuppressed populations.
NVX-CoV2372 is in Phase 2 clinical development. The program includes one completed Phase 2 trial, and no active trials are currently listed. It remains an investigational agent and has not been approved by the FDA for any use.
NVX-CoV2372 has been studied in the completed Phase 2 trial NCT06027229, titled Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations. The trial enrolled 21 participants in the United States, included adults 18 years and older of all sexes, and used a controlled design.